Descripción del proyecto
Medicina de precisión para la esclerosis múltiple
La esclerosis múltiple (EM) es un trastorno inflamatorio crónico del sistema nervioso central y que está asociado a la destrucción de la mielina y al daño neuroaxonal. A medida que las neuronas pierden gradualmente su capacidad de transmitir señales, las personas con EM padecen diferentes síntomas y enfermedades concomitantes discapacitantes. La naturaleza heterogénea de la EM indica que no existe un enfoque de gestión y tratamiento universal. El proyecto CLAIMS, financiado por el programa Horizonte Europa, tiene por objeto hacer realidad la medicina de precisión para las personas con EM. Su consorcio creará una plataforma de diagnóstico que ofrezca una visión integral y holística del estado de salud del paciente mediante tecnologías de diagnóstico avanzadas. El objetivo es predecir la evolución de la EM de forma individual con diferentes tratamientos, así como mejorar el resultado clínico de los pacientes.
Objetivo
Multiple sclerosis (MS) is a devastating immune-mediated disorder of the central nervous system. Since there is no cure available yet for MS, the primary therapeutic goal for MS patients is to slow down disability progression and to reduce relapses at early stages of the disease. Despite 19 available disease modifying treatments (DMTs), the large heterogeneity of the disease, further complicated by the high prevalance of comorbidities and multipharmacy, and the limited understanding of the working mechanisms DMT thereon results in a poor and variable treatment response in a real-world setting. The CLAIMS project is a public-private partnership aiming to address this and make precision medicine for MS patients a reality through data-driven prognosis and treatment advice, in order to better slow down disease progression and eventually conversion to progressive MS. We will develop, validate and submit for regulatory approval a companion diagnostic platform, which offers the MS care team a holistic view of the patient through the visualization of the clinical and subclinical biomarkers and the prediction of the expected disease trajectory under different treatments. For biomarker extraction and treatment prediction, state-of-the-art technologies that allow a reliable and scalable implementation across the world will be used. We believe this platform will initiate the paradigm shift from a trial-and-error, experienced-based treatment of MS patients to a first-time-right, value-based holistic treatment management, and will, hence, improve patient outcomes at a lower total cost of care, enhance patient experience and improve the well-being of the care team.
Ámbito científico
Palabras clave
Programa(s)
- HORIZON.2.1 - Health Main Programme
- HORIZON.2.1.7 - Innovative Health Initiative
Convocatoria de propuestas
HORIZON-JU-IHI-2022-01-single-stage
Consulte otros proyectos de esta convocatoriaRégimen de financiación
HORIZON-JU-RIA - HORIZON JU Research and Innovation ActionsCoordinador
10117 Berlin
Alemania